Status:
COMPLETED
Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)
Lead Sponsor:
Topokine Therapeutics, Inc.
Conditions:
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
Eligibility:
All Genders
40-70 years
Phase:
PHASE2
Brief Summary
This study will test whether XAF5 (XOPH5) ointment, applied once daily to the lower eyelids for 10 weeks, reduces the prominence of lower eyelid fat in adults with moderate to severe steatoblepharon (...
Eligibility Criteria
Inclusion
- Inclusion Criteria (abbreviated):
- Moderate to severe lower eyelid steatoblepharon (LESS score of 2-4 bilaterally)
- Men and women 40-70 years old
- Healthy facial skin
- Must understand and provide informed consent
- Exclusion Criteria (abbreviated):
- Best corrected visual acuity worse than 20/40 in either eye
- Regular use of ophthalmic medication in either eye
- Planned use of contact lenses during the study
- Any history of lower eyelid surgery
Exclusion
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT02230761
Start Date
September 1 2014
End Date
December 1 2014
Last Update
February 8 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Topokine Therapeutics Clinical Study Centers
Boston, Massachusetts, United States, 02111